Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Collagen Solutions PLC to work with renowned burns unit

The med-tech group is developing a range of collagen-based medical implants
Collagen Solutions PLC to work with renowned burns unit
The two organisations will research a better way to treat burn injuries

--ADDS SHARE PRICE AND BROKER COMMENT---

Collagen Solutions PLC (LON:COS) has established a research collaboration with the Blond McIndoe Research Foundation (BMRF), a not-for-profit burns treatment specialist based at the Queen Victoria Hospital, East Grinstead.

The med-tech group is developing a range of collagen-based medical implants and the two will investigate how to use Collagen’s products to find treatments that reduce the side effects of skin grafts.

Collagen added it sees the combination of BMRF's experience in culturing cells specifically for treatment of burns and the use of high quality medical grade collagen as a potentially effective treatment.

Dr Stewart White, Collagen Solutions’ chief executive, said the care and treatment of burns represented a significant clinical need.

BMRF's experience in the treatment of burns and wound care using the patient's own cells is truly world-leading, he said.

Initially, the project will determine that collagen formulations can provide a successful scaffold for these living cells, he added, after which the two organisations will work on a delivery method.

Broker Panmure said: "Today’s news further demonstrates, in our view, the breadth of opportunity for Collagen Solutions’ technologies. We retain our investment thesis unchanged."

The broker has a 'buy' stance and a target price of 10p.

Shares added  4% to stand at 6.50p on the day.

PhilW.jpg
Why Invest In Collagen Solutions PLC? Read More Here

Register here to be notified of future COS Company articles
View full COS profile

Collagen Solutions PLC Timeline

Article
July 11 2016
Newswire
June 09 2016

Related Articles

immupharma-_kiss_pic_with_mum.png
March 01 2016
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....
Clean room
June 14 2016
Contracted business is already in excess of £9 million this year, with a strong pipeline of further business opportunities being pursued across all areas of the group
antibiotic.jpg
March 02 2016
In all 1,200 patients will take part in the global trials run by Motif’s partner Covance.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.